-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, UqZKW+guJwsSBsCZnntOmaNxt0QunBr0tH1ryGmkZGKzxcT79YyPqgtASsAis02+ wYnE8DycyrtxFdAdAUOedg== 0001144204-05-016641.txt : 20050520 0001144204-05-016641.hdr.sgml : 20050520 20050520162011 ACCESSION NUMBER: 0001144204-05-016641 CONFORMED SUBMISSION TYPE: 10QSB PUBLIC DOCUMENT COUNT: 6 CONFORMED PERIOD OF REPORT: 20050331 FILED AS OF DATE: 20050520 DATE AS OF CHANGE: 20050520 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MOLECULAR DIAGNOSTICS INC CENTRAL INDEX KEY: 0000075439 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 364296006 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10QSB SEC ACT: 1934 Act SEC FILE NUMBER: 000-00935 FILM NUMBER: 05848496 BUSINESS ADDRESS: STREET 1: 414 NORTH ORLEANS STREET STREET 2: SUITE 502 CITY: CHICAGO STATE: IL ZIP: 60610 BUSINESS PHONE: 4078490290 MAIL ADDRESS: STREET 1: 414 NORTH ORLEANS STREET STREET 2: SUITE 502 CITY: CHICAGO STATE: IL ZIP: 60610 FORMER COMPANY: FORMER CONFORMED NAME: AMPERSAND MEDICAL CORP DATE OF NAME CHANGE: 19990527 FORMER COMPANY: FORMER CONFORMED NAME: BELL NATIONAL CORP DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: PACIFIC COAST HOLDINGS INC DATE OF NAME CHANGE: 19830303 10QSB 1 v018881_10qsb.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-QSB (Mark One) |X| QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2005 |_| TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from _________ to ____________. Commission File number 0-935 MOLECULAR DIAGNOSTICS, INC. --------------------------- (Exact Name of Small Business Issuer as Specified in Its Charter) Delaware 36-4296006 -------- ---------- (State or Other Jurisdiction of (I.R.S. Employer Incorporation or Organization) Identification No.) 414 North Orleans Street, Suite 502 Chicago, IL 60610 ----------------- (Address of Principal Executive Offices) (312) 222-9550 -------------- (Issuer's Telephone Number, including Area Code) N/A --- (Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report) Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes |X| No |_| The number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date: COMMON STOCK, $0.001 PAR VALUE, AT MAY 13, 2005: 111,375,204 MOLECULAR DIAGNOSTICS, INC. QUARTERLY REPORT ON FORM 10-QSB TABLE OF CONTENTS
Page PART I. -- FINANCIAL INFORMATION Item 1. Financial Statements a) Consolidated Balance Sheets -- March 31, 2005 (unaudited) and December 31, 2004 ................................................ 3 b) Consolidated Statements of Operations -- Three months ended March 31, 2005 and March 31, 2004 (unaudited) ....................................... 4 c) Consolidated Statements of Cash Flows -- Three months ended March 31, 2005 and March 31, 2004 (unaudited) ....................................... 5 d) Notes to Consolidated Financial Statements ............................... 6 Item 2. Management's Discussion and Analysis or Plan of Operation ................................................. 19 Item 3. Controls and Procedures ............................................ 23 PART II. -- OTHER INFORMATION Item 1. Legal Proceedings .................................................. 23 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds ........ 23 Item 3. Defaults upon Senior Securities .................................... 24 Item 4. Submission of Matters to a Vote of Security Holders ................ 24 Item 5. Other Information .................................................. 24 Item 6. Exhibits ........................................................... 25 SIGNATURES .................................................................. 25 EXHIBIT INDEX ............................................................... 26
2 PART I. -- FINANCIAL INFORMATION Item 1. Financial Statements MOLECULAR DIAGNOSTICS, INC. CONSOLIDATED BALANCE SHEETS (Dollars in thousands)
March 31, December 31, 2005 2004 ---------- ---------- (Unaudited) Assets Current Assets: Cash and cash equivalents ...................................................................... $ 3 $ 11 Accounts receivables, net of allowance for doubtful accounts of $0 at March 31, 2005 and December 31, 2004 ............................................................ 10 30 Inventories .................................................................................... 48 48 Prepaid financings costs ....................................................................... 45 80 Prepaid expenses and other current assets ...................................................... 13 14 ---------- ---------- Total current assets ............................................................. 119 183 Fixed Assets, net .............................................................................. 289 326 Other Assets: Licenses, patents and technology, net of amortization .......................................... 20 20 ---------- ---------- Total assets ..................................................................... $ 428 $ 529 ========== ========== Liabilities and Stockholders' Equity (Deficit) Current Liabilities: Accounts payable ............................................................................... $ 4,357 $ 4,426 Accrued payroll costs .......................................................................... 977 1,084 Accrued expenses ............................................................................... 2,003 1,944 Deferred revenue ............................................................................... 25 25 Due to stockholder ............................................................................. 36 38 Lease obligation ............................................................................... 110 110 Notes payable--related party ................................................................... 70 70 Notes payable .................................................................................. 5,164 4,955 ---------- ---------- Total current liabilities ........................................................ 12,742 12,652 ---------- ---------- Stockholders' Equity (Deficit): Preferred stock, $0.001 par value; 10,000,000 shares authorized; 1,119,192 shares issued and outstanding at March 31, 2005 and December 31, 2004 (Liquidation value of all classes of preferred stock $9,510,022) ......................................................... 7,767 7,767 Common stock, $0.001 par value; 300,000,000 shares authorized; 109,400,625 and 99,792,292 shares issued and 109,208,537 and 99,600,204 shares outstanding at March 31, 2005 and December 31, 2004, respectively ............................................................................. 110 100 Additional paid-in-capital ..................................................................... 46,910 45,961 Treasury stock; 192,088 shares at March 31, 2005 and December 31, 2004 ......................... (327) (327) Accumulated deficit ............................................................................ (66,717) (65,565) Accumulated comprehensive loss-- Cumulative translation adjustment ..................................................... (57) (59) ---------- ---------- Total stockholders' equity (deficit) ............................................. (12,314) (12,123) ---------- ---------- Total liabilities and stockholders' equity (deficit) ............................. $ 428 $ 529 ========== ==========
The accompanying notes are an integral part of these consolidated financial statements. 3 MOLECULAR DIAGNOSTICS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except share and per share amounts)
Three Months Ended March 31, --------- 2005 2004 ------------ ------------ (Unaudited) Net revenues ......................................... $ 40 $ 53 Operating expenses Cost of revenues ............................ -- -- Research and development .................... 72 157 Selling, general, and administrative expenses 717 1,415 ------------ ------------ Total operating expenses ............... 789 1,572 ------------ ------------ Operating loss ....................................... (749) (1,519) Other income (expense): Interest expense - related party ............ (2) (40) Interest expense ............................ (401) (660) Gain on currency conversion ................. -- 10 Restructuring settlements ................... -- 161 ------------ ------------ Total other income (expense) ........... (403) (529) ------------ ------------ Loss before income taxes ............................. (1,152) (2,048) Income tax expense ................................... -- -- ------------ ------------ Net loss ............................................ (1,152) (2,048) Preferred stock dividend ............................. (225) (312) ------------ ------------ Total dividends ...................................... (225) (312) ------------ ------------ Net loss applicable to common stockholders ........... $ (1,377) $ (2,360) ============ ============ Basic and diluted net loss per common share .......... $ (0.01) $ (0.04) ============ ============ Weighed average number of common shares outstanding .. 104,343,116 55,812,649 ============ ============
The accompanying notes are an integral part of these consolidated financial statements. 4 MOLECULAR DIAGNOSTICS, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (Dollars in thousands)
Three Months Ended March 31, --------- 2005 2004 ---------- ---------- (Unaudited) Operating Activities: Net loss ................................................................... $ (1,152) $ (2,048) Adjustments to reconcile net loss to net cash used for operating activities: Amortization of debt discount ...................................... 176 464 Depreciation and amortization ...................................... 34 178 Amortization of fees ............................................... 34 119 (Gain) loss on sale of fixed assets ................................ 3 (99) Note issued in payment of an expense ............................... 40 33 Warrants issued in settlement ...................................... 421 -- Return of fixed assets in exchange for relief of indebtedness ...... -- 149 Stocks, warrants and options issued to non-employees for services .. 16 556 Changes in assets and liabilities: Accounts receivable, net ...................................... 20 (13) Inventories ................................................... -- (6) Due from stockholder .......................................... (1) 35 Prepaid expenses and other current assets ..................... 1 -- Checks issued in excess of amounts on deposit ................. -- (5) Accounts payable .............................................. (69) (532) Lease Obligation .............................................. -- (142) Accrued expenses .............................................. (48) 95 ---------- ---------- Net cash used for operating activities ...................................... (525) (1,216) ---------- ---------- Cash used in investing activities: Purchases of fixed assets ................................................... -- (29) ---------- ---------- Net cash used for investing activities ...................................... -- (29) ---------- ---------- Cash flows from financing activities: Proceeds from issuance of convertible notes payable ......................... -- 1,292 Net proceeds from issuance of common stock .................................. 521 -- Payment of notes payable .................................................... (4) (30) Proceeds from sale of fixed assets .......................................... -- 28 ---------- ---------- Net cash provided by financing activities ................................... 517 1,290 ---------- ---------- Effect of exchange rate changes on cash and cash equivalents ................ -- -- ---------- ---------- Net increase (decrease) in cash and cash equivalents ........................ (8) 45 Cash and cash equivalents at the beginning of period ........................ 11 -- ---------- ---------- Cash and cash equivalents at end of period .................................. $ 3 $ 45 ========== ========== Supplemental disclosure of cash flow information: Cash paid during the period for: Interest ................................................................... $ 25 $ 2 Non-cash transactions during the period for: Financing costs ............................................................. $ 16 $ 108 Preferred stock and cumulative dividends converted into common stock ........ $ -- $ 3,346
The accompanying notes are an integral part of these consolidated financial statements. 5 MOLECULAR DIAGNOSTICS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Note 1. Organization Molecular Diagnostics, Inc. ("MDI" or the "Company") was incorporated as Ampersand Medical Corporation in Delaware in December 1998 as the successor to Bell National Corporation ("Bell National"). Bell National was incorporated in California in 1958, and was the continuing legal entity following its acquisition of InPath, LLC, a development-stage company engaged in the design and development of medical instruments and related tests, in December 1998. Bell National then merged into the Company, which was then operating under the Ampersand name, in 1999. On September 25, 2001, following the Company's acquisition of AccuMed International, Inc. ("AccuMed") via the merger of AccuMed into a wholly-owned subsidiary of MDI, the Company changed its corporate name to Molecular Diagnostics, Inc. in order to better represent its operations and products. The name change was effected through a merger with a separate wholly-owned subsidiary. MDI retained its Certificate of Incorporation in the merger, except as amended to reflect its new name, bylaws and capitalization. MDI is a bio-molecular diagnostics company engaged in the design, development and commercialization of cost-effective screening systems to assist in the early detection of cancer. MDI is currently focused on the design, development and marketing of its InPath(TM) System and related image analysis systems. The InPath System and related products are intended to detect cancer and cancer-related diseases, and may be used in a laboratory, clinic, or doctor's office. In addition to AccuMed and Oncometrics Imaging Corp., a wholly-owned subsidiary of AccuMed, MDI had another wholly-owned subsidiary, Samba Technologies, Sarl ("Samba"). MDI lost all rights and title to the assets of Samba upon completion of the former subsidiary's bankruptcy liquidation sale in December 2003. The Company has incurred significant operating losses since its inception. Management expects that significant on-going operating expenditures will be necessary to successfully implement MDI's business plan and develop, manufacture and market its products. These circumstances raise substantial doubt about MDI's ability to continue as a going concern. Implementation of the Company's plans and its ability to continue as a going concern depend upon its securing substantial additional financing. During the first three months of 2005, MDI raised net proceeds of $521,050 through the sale of common stock. Management's plans include efforts to obtain additional capital. If the Company is unable to obtain adequate additional financing or generate profitable sales revenues, it may be unable to resume its product development and other activities and may be forced to cease operations. Note 2. Basis of Presentation The consolidated financial statements for the periods ended March 31, 2005 and 2004 included herein are unaudited. Such financial statements reflect, in the opinion of management, all adjustments necessary to present fairly the financial position and results of operations as of and for the periods indicated and in order to make the financial statements not misleading. All such adjustments are of a normal recurring nature. These interim results are not necessarily indicative of the results to be expected for the fiscal year ending December 31, 2005 or for any other period. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission. These financial statements should be read in conjunction with the audited financial statements and the notes thereto included in our Annual Report on Form 10-KSB for the fiscal year ended December 31, 2004, as filed with the SEC. Note 3. Summary of Significant Accounting Principles The accounting policies and principles management believes are most critical to aid in understanding and evaluating the Company's reported financial results include the following: 6 Principles of Consolidation. The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation. Use of Estimates. The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Revenue Recognition. MDI recognizes revenue in accordance with Staff Accounting Bulletin No. 104, "Revenue Recognition," when the following criteria are met: shipment of a product or license to customers has occurred and there are no remaining Company obligations or contingencies; persuasive evidence of an arrangement exists; sufficient vendor-specific, objective evidence exists to support allocating the total fee to all elements of the arrangement; the fee is fixed or determinable; and collection is probable. Revenue from ongoing client maintenance is recognized ratably over the post-contract support term, which is generally 12 months. Revenue from training services and professional services is recognized when the service is completed. Revenue from implementation and installation services is recognized using the percentage of completion method. Implementation and installation services are generally completed within 120 days. Research and Development Costs. Research and development costs are charged to operations as incurred. MDI conducts a portion of its research activities under contractual arrangements with scientists, researchers, universities, and other independent third parties. Foreign Currency Translation. The functional currency of the Company's foreign operations is the local currency. Accordingly, all assets and liabilities are translated into U.S. dollars using year-end exchange rates, and all revenues and expenses are translated using average exchange rates during the year. Net Loss Per Share. Basic loss per share is calculated based on the weighted-average number of outstanding common shares. Shares issued and shares reacquired during the period are weighted for the portion of the period that they were outstanding. Diluted loss per share is calculated based on the weighted-average number of outstanding common shares plus the effect of dilutive common shares. MDI's calculation of diluted net loss per share as reported excludes potential common shares, as the effect would be anti-dilutive. Restructuring Settlements. Restructuring settlements reflect the difference between the actual settlement amounts for various litigation and creditor payment matters and the amounts recorded on the Company's financial statement as the amount due. Share-Based Payment. In December 2004, FASB issued Statement of Financial Accounting Standards No. 123(revised), "Share-Based Payment" ("SFAS No. 123(R)"), which revised SFAS No. 123, "Accounting for Stock-Based Compensation" ("SFAS No. 123"). SFAS No. 123(R) establishes accounting standards for transactions in which a company exchanges its equity instruments for goods or services. In particular, the statement will require companies to record compensation expense for all share-based payments, such as employee stock options, at fair market value. This statement is effective as of the beginning of the next fiscal year that begins after December 15, 2005. Adoption of this financial statement is not expected to have a material impact on the Company's consolidated financial position or results of operations. Note 4. Licenses, Patents and Technology Licenses, patents, and purchased technology are recorded at their acquisition cost. Costs to prepare patent filings are expensed when incurred. Costs related to abandoned patents or denied patent applications are written off at the time of abandonment or denial. Amortization is begun as of the date of acquisition or upon the grant of the final patent. Costs are amortized over the asset's useful life, which ranges from two to 17 years. At each annual balance sheet date or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable, management of the Company evaluates the recoverability of such assets. 7 Licenses, patents, and technology are as follows: (in thousands) March 31, December 31, 2005 2004 ---------- ---------- (unaudited) Licenses .................... $ 20 $ 20 Patent costs ................ 133 133 MDI Technology Agreement .... -- -- LabCorp Technology Agreement 260 260 ---------- ---------- Subtotal ................... 413 413 Less accumulated amortization (393) (393) ---------- ---------- Total ...... $ 20 $ 20 ========== ========== In 2004, MDI was party to a legal settlement with MonoGen, Inc. involving technology owned by MDI's subsidiary, AccuMed. The dispute was resolved, resulting in the transfer to MonoGen of all of MDI's rights and title to certain AccuMed intellectual property. The transferred technology is not used in the Company's InPath(TM) cervical screening system. The settlement resulted in a net $5,919,000 loss reflected in adjustments to the MDI Technology Agreement and accumulated amortization balances as of December 31, 2004. In 2004, MDI was also party to a legal settlement with Invirion, Inc. and Dr. Bruce Patterson over the validity of a technology license. Pursuant to the settlement agreement, MDI agreed to the cancellation of the license, which resulted in a net $569,000 loss reflected in adjustments to the license and accumulated amortization balances as of December 31, 2004. For the three months ended March 31, 2005 and 2004, amortization expense was $0 and $131,000, respectively. Note 5. Accrued Expenses Accrued expenses included the following: (in thousands) March 31, December 31, 2005 2004 ---------- ---------- (unaudited) Accrued interest ................ $ 1,051 $ 994 Accrued interest--related party . 27 25 Accrued settlement costs ........ 438 438 Accrued franchise and other taxes 476 476 Other accrued expenses .......... 11 11 ---------- ---------- Total ................... $ 2,003 $ 1,944 ========== ========== MDI was delinquent in paying a portion of federal and state employee and employer payroll taxes for 2003, 2002, and 2001. The delinquent federal payroll taxes relating to 2003 and 2002 were paid in full in April 2004. The delinquent federal payroll taxes relating to 2001 were paid in full in January 2005. The Company owed $0 and $97,000 as of March 31, 2005 and December 31, 2004, respectively, for 2001 federal payroll taxes, which were included in accrued payroll costs in the accompanying December 31, 2004 balance sheet. MDI is also delinquent in filing certain federal and state income tax returns for 2003 and 2002 and is working to complete and file the returns. MDI does not expect to owe federal and state income taxes for 2003 and 2002. The delinquent federal and state income tax returns for 2001 were filed in March 2005 with zero tax due. 8 Note 6. Notes Payable--Related Parties Notes payable to related parties consisted of: (in thousands)
March 31, December 31, 2005 2004 ---------- ---------- (unaudited) Northlea Partners, Ltd., $25,000 Promissory Note issued August 6, 2001; interest rate 15% per annum ............................................. $ 25 $ 25 Northlea Partners, Ltd., $15,000 Promissory Note issued September 20, 2001; interest rate 9% per annum .............................................. 15 15 Northlea Partners, Ltd., $15,000 Bridge II Convertible Promissory Note issued May 1, 2003; interest rate 12% per annum (see description under Bridge II Notes in Note 7-Notes Payable for other terms and conditions) ........... 15 15 Robert Shaw, $25,000 Promissory Note issued September 20, 2001; interest rate 9% per annum ............................................................ 15 15 ---------- ---------- $ 70 $ 70 ========== ==========
Peter Gombrich Amounts Due. Peter Gombrich, the Company's former Chairman and CEO, was owed $36,481 and $37,299 at March 31, 2005 and December 31, 2004, respectively, for previous advances to the Company. MDI has classified the amount due to Mr. Gombrich under the current liabilities heading "Due to stockholder" in the accompanying balance sheets. Carrying Amounts. Management believes it is not practicable to estimate the fair value of the notes payable-related parties due to the uncertainty regarding repayment or possible conversion and the Company's current financial condition. Note 7. Notes Payable Notes payable to unrelated parties consisted of: (in thousands)
March 31, December 31, 2005 2004 ---------- ---------- (unaudited) Bridge I Convertible Promissory Notes; due December 31, 2002; interest rate 7% per annum; convertible into common stock at 75% of the market price on date of conversion; beneficial conversion feature valued at $1,042,000 at June 30, 2002; warrants at an exercise price of $0.25 per share; additional warrants at an exercise price equal to 150% of note conversion price ................ $ 750 $ 750 Bridge II Convertible Promissory Notes; due July 31, 2003; interest rate 12%/15% per annum; convertible into common stock at $0.10 or $0.15 per share; beneficial conversion feature valued at $1,777,000 and $330,000 at December 31, 2003 and December 31, 2002, respectively; warrants at an exercise price of $0.15 or $0.20 per share ........................... 1,285 1,285 Bridge III Convertible Promissory Notes; due December 31, 2008; interest rate 10% per annum; convertible into common stock at $0.10 per share; beneficial conversion feature valued at $1,604,000 at June 30, 2004; warrants at an exercise price of $0.15 per share ................................................... 351 268 Bridge IV Convertible Promissory Notes; due December 31, 2008; interest rate 10% per annum; convertible into common stock at $0.10 per share; beneficial conversion feature valued at $1,791,000 at June 30, 2004; warrants at an exercise price of $0.15 per share .................................... 1,177 1,085 Monsun, AS $500,000 Promissory Note issued November 1, 2000; interest rate 20% per annum, compounded into principal amount; beneficial conversion feature valued at $125,000 at November 1, 2000 ..................................................... 822 782 MonoGen, Inc. $305,000 Promissory Note issued October 14, 2004; interest rate at 14% per annum; first installment of $25,000 due November 1, 2004 with monthly 9 principal and interest installments of $10,000 thereafter; due January 1, 2007 ...... 305 305 O.P., LLC $29,390 Promissory Note issued May 12, 2003; interest rate at 7% per annum; monthly principal payments of $1,316 plus interest commencing June 1, 2003; due April 2005 ...................................................................... 3 6 Ungaretti and Harris LLP $211,368 Secured Promissory Note issued May 8, 2003; interest rate at 12% per annum; due September 30, 2003 ....................................... 149 149 Ernst & Young LLP $30,800 Promissory Note issued July 17, 2003; interest rate at 12% per annum commencing January 1, 2003; due December 31, 2003 ......................... 31 31 Ventana Medical Systems, Inc. $62,946 Promissory Note issued November 30, 2003; due December 31, 2003; interest at 8% per annum payable after December 31, 2003 ..... 21 21 Xillix Technologies Corporation $361,000 Promissory Note issued June 26, 1998; interest rate Canadian Prime plus 6% per annum; represents a debt of AccuMed ................. 34 34 Western Economic Diversification $221,000 Promissory Note issued June 1989; no interest; represents a debt of Oncometrics .......................................... 236 239 ---------- ---------- $ 5,164 $ 4,955 ========== ==========
Bridge I. In 2002, MDI issued an aggregate $3,185,000 in Bridge I Convertible Promissory Notes to accredited investors. The notes bear interest at the rate of 7% per annum and are convertible at any time into the common stock of MDI at a conversion price equal to 75% of the market price of the Company's common stock on the date of conversion. In addition, MDI issued to each holder a warrant that entitled each such holder to purchase one share of common stock at an exercise price of $0.25 per share for each dollar of principal. MDI calculated a fair value of $99,950 for these warrants using the fair value interest rate method and recorded this amount as additional interest expense during 2002. In addition, at the time of conversion of the note, each holder is entitled to receive a warrant to purchase one share of common stock for each four shares of common stock into which the note converts at an exercise price equal to 150% of the conversion price of the note. MDI has not determined a value for these warrants as of March 31, 2005. Since the conversion price of the note is at a 25% discount to the market price of the common stock of MDI, the holder is considered to have a beneficial conversion feature. MDI determined the value of the beneficial conversion feature to be $1,042,000 at June 30, 2002. In February 2003, a note holder, NeoMed Innovations III, converted $1,060,000 in principal amount of Bridge I notes into Bridge II notes. In November 2003, two Bridge I note holders converted $50,000 in principal amount of notes and $5,287 in accrued interest into 368,579 shares of unregistered common stock. Management extended a written offer, dated October 10, 2003, to the Bridge I noteholders to convert their notes and accrued interest into common shares at a conversion rate of $0.15 per share. In addition, the Bridge I holders were offered warrants to purchase one new share for every four shares acquired by the noteholder upon exercise of such holder's conversion rights under the notes. This offer continued to remain outstanding as of March 31, 2005. During the twelve months ended December 31, 2004, holders of $1,325,000 principal amount of Bridge I convertible promissory notes elected to convert their notes and related accrued interest of approximately $173,000 into 9,985,182 shares of unregistered common stock. The remaining $750,000 in principal Bridge I notes remained unconverted and outstanding at March 31, 2005. Bridge II. Beginning in October 2002, MDI began an issue of up to $4,000,000 in Bridge II Convertible Promissory Notes to accredited investors. MDI issued $550,000 in Bridge II notes as of December 31, 2002. From January 1, 2003 through the closing of the offering on December 5, 2003, MDI issued Bridge II notes in the principal amount of: $1,980,200 in exchange for cash, $1,060,000 as a conversion of a Bridge I Convertible Promissory Note (see discussion above) and $305,667 in exchange for a note payable to Peter P. Gombrich, the Company's then-Chairman, for a total issuance during fiscal year 2003 of $3,345,867. The notes bear interest at a rate of 12% per annum payable at the maturity date in kind in the form of shares of common stock of MDI. The Company granted the holders a junior security position in all of its assets. The notes are convertible at any time into the common stock of MDI. The note conversion price and the value of common shares paid in kind as interest for the first $1,000,000 in principal amount of cash subscriptions, determined on a "first come - first served basis," is $0.10 per share. The note conversion price and the value of common shares paid in kind as interest for the remaining $3,000,000 of principal amount of notes in the series is $0.15 per share. The conversion prices of the notes issued during 2002 and 2003 were less than the market price of the common stock when the notes were issued; therefore, the holders are considered to have a beneficial conversion feature. MDI determined the value of the beneficial conversion feature to be $1,777,200 and $330,000 at December 31, 2003 and 2002, respectively. The value was recorded as a reduction of the debt and was amortized as additional interest over the life of the notes. MDI recorded 10 additional interest expense of $334,909 and $1,826,743 to reflect amortization of the discount during the twelve months ended December 31, 2004 and 2003, respectively. At the time MDI completes significant additional funding plans, as outlined in the subscription agreement for the Bridge II notes, each holder of Bridge II notes is entitled to receive a warrant to purchase one share of the common stock of the Company for each four shares of common stock into which the note is convertible at an exercise price of $0.15 per share for notes in the class pertaining to the first $1,000,000 in subscriptions and $0.20 for the remaining $3,000,000 in note principal subscriptions. In September 2003, an amendment to the Bridge II convertible promissory notes was sent to holders requesting an extension of the notes to July 31, 2004. As additional consideration for the extension, holders were offered an increase in the interest rate from 12% to 15%. In addition, an amendment to the indenture also offered an increase in the warrant coverage ratio from 25% to 33%. The Bridge II offering was closed as of December 5, 2003. For the 12 months ended December 31, 2004, holders of $2,146,000 principal amount of Bridge II convertible promissory notes elected to convert their notes and related accrued interest of approximately $251,000 into 17,619,242 shares of unregistered common stock. Included in the above conversion amounts are amounts due Peter P. Gombrich, the Company's former Chairman, of $305,667 in Bridge II principal and $11,431 in accrued interest thereon, which were converted into an aggregate 2,113,987 shares of unregistered common stock. The remaining $1,300,000 in principal Bridge II notes remained unconverted and outstanding at March 31, 2005. Bathgate Capital Partners, LLC - Bridge III. Beginning in January 2004, Bathgate Capital Partners, LLC began an offering of a maximum of $4,000,000 and a minimum of $1,500,000 in Bridge III Convertible Promissory Notes to accredited investors on behalf of the Company. The notes bear interest at 10% per annum payable, on a semi-annual basis, in kind in the form of shares of common stock for the first two years and then in cash for the remaining three years until due December 31, 2008. The note conversion price and the value of common shares paid in kind as interest is $0.10 per share. The notes are convertible at any time into the common stock of MDI, although the notes will automatically convert if the last sales price of the stock is $0.30 or higher for twenty consecutive trading days, the daily average trading volume is at least 250,000 shares, and the underlying shares are registered for sale. The holders were also granted a security interest in all of the Company's assets. MDI granted each note holder the right to receive 25% warrant coverage on all money invested; therefore, for every $100,000 invested, an investor will receive warrants to purchase 25,000 shares of common stock at an exercise price of $0.15 per share. The warrants expire on December 31, 2008. The Bridge III offering documents provided that funds raised would not be released from escrow until the following requirements were met: o A minimum investment of $1,500,000 had been reached; o The $190,000 Convertible Promissory Note held by Suzanne Gombrich, wife of Peter Gombrich, was converted into common shares; o A portion of the Bridge II Convertible Promissory Note holders converted their notes into common shares; and o Peter P. Gombrich, MDI's then-current Chairman and CEO, would resign his position as CEO of the Company. With the exception of the conversion of Suzanne Gombrich's $190,000 note, which was converted following stockholder approval of an increase in the number of authorized shares of common stock of the Company in July 2004, these requirements were satisfied on April 2, 2004 and the Company issued $1,500,000 in convertible promissory notes in exchange for cash. The funds were used for repayment of a $1 million convertible note held by Suzanne Gombrich, payment of taxes, and working capital. On May 21, 2004, the Company issued an additional $162,500 in Bridge III notes in exchange for cash. The conversion prices of the notes issued during 2004 were less than the market price of the common stock when the notes were issued; therefore, the holders are considered to have a beneficial conversion feature. MDI determined the value of the beneficial conversion feature to be $1,604,000 at June 30, 2004. The value was recorded as a reduction of the debt and will be amortized as additional interest over the life of the notes. MDI recorded additional interest expense of $83,436 and $208,595 to reflect amortization of the discount during the 3 months ended March 31, 2005 and the 12 months ended December 31, 2004, respectively. At the conclusion of the offering, the Company had issued an aggregate $1,662,500 in 11 principal amount of Bridge III convertible promissory notes in exchange for cash, all of which remained unconverted and outstanding at March 31, 2005. Bridge IV. Beginning in February 2004, MDI began a separate offering of Bridge IV Convertible Promissory Notes to accredited investors. The notes bear interest at 10% per annum payable, on a semi-annual basis, in kind in the form of shares of common stock for the first two years and then in cash for the remaining three years until the December 31, 2008 maturity date. The note conversion price and the value of common shares paid in kind as interest is $0.10 per share. The conversion prices of the notes during 2004 were less than the market price of the common stock when the notes were issued; therefore, the holders are considered to have a beneficial conversion feature. MDI determined the value of the beneficial conversion feature to be $1,791,000 at June 30, 2004. The value was recorded as a reduction of the debt and will be amortized as additional interest over the life of the notes. MDI recorded additional interest expense of $92,196 and $302,288 to reflect amortization of the discount during the 3 months ended March 31, 2005 and the 12 months ended December 31, 2004, respectively. The notes are convertible at any time into the common stock of MDI, although the notes will automatically convert if the last sales price of the stock is $0.30 or higher for twenty consecutive trading days, the daily average trading volume is at least 250,000 shares, and the underlying shares are registered for sale. The holders were also granted a security interest in all of the Company's assets. MDI granted each note holder the right to receive 25% warrant coverage on all money invested; therefore, for every $100,000 invested, an investor will receive warrants to purchase 25,000 shares of common stock at an exercise price of $0.15 per share. The warrants expire on December 31, 2008. At the conclusion of the offering, the Company had issued an aggregate $2,573,500 in principal amount of Bridge IV convertible promissory notes in exchange for cash, all of which remained unconverted and outstanding at March 31, 2005. Monsun. On November 1, 2000, MDI issued a convertible promissory note to Monsun, AS ("Monsun") in exchange for $500,000 in cash. The note bears interest at the rate of 20% per year and was originally due 12 months from the date of issue. The note is convertible into common stock, any time after the expiration of the first 180 days of the loan term, at a conversion price of $1.00 per share. On October 31, 2001, Monsun and MDI agreed to the first extension of the maturity date of the note until January 31, 2002. As consideration for the first extension agreement, MDI issued a three-year warrant to Monsun, entitling the holder to purchase 100,000 shares of common stock of MDI at an exercise price of $0.60 per share. On January 31, 2002, Monsun and MDI agreed to the second extension of the maturity date of the note. As consideration for the second extension agreement, MDI issued a three-year warrant to Monsun, entitling the holder to purchase 200,000 shares of common stock of MDI at an exercise price of $0.30 per share. A fair value of $4,110 for the warrant was calculated using the fair value interest rate method and was recorded as additional interest expense during 2002. On April 1, 2002, Monsun and MDI agreed to the third an final extension of the maturity date until July 31, 2002. As consideration for the third extension agreement, MDI issued a five-year warrant to Monsun, entitling the holder to purchase 200,000 shares of common stock of MDI at an exercise price of $0.70 per share. A fair value of $8,287 for the warrant was calculated using the fair value interest rate method and was recorded as additional interest expense during 2002. In November 2002, MDI issued 200,000 shares of its common stock as a default penalty on the note. A fair value of $42,000 for the shares was calculated using the market price of the common stock on the date the shares were issued and recorded as financing expenses during 2002. MDI made payments against the principal of the note amounting to $117,266 and recorded interest expense, in addition to the amounts mentioned above, of $80,200 during 2002. In January 2003, Monsun initiated a legal action against Peter Gombrich, MDI's then-Chairman, as a personal guarantor on the note, in an attempt to collect the unpaid principal balance of the note. Monsun was successful in obtaining a legal judgment of approximately $675,000 related to the note balance and accrued interest against Mr. Gombrich as personal guarantor. In addition, Monsun was granted an award of approximately $438,000 for attorneys' fees against Peter Gombrich as the personal guarantor. The award for legal fees has been recorded as an accrued expense. (See Note 5 - Accrued Expenses) Those judgments remain unsatisfied. Monsun has not filed suit directly against the Company to recover any amounts due under the note or otherwise. MonoGen, Inc. In October 2004, MDI entered into a settlement agreement with MonoGen, Inc. relating to an arbitration proceeding brought against AccuMed and Oncometrics for alleged breaches in connection with certain license and related agreements among the parties. As part of the settlement, MDI issued a 12 promissory note to MonoGen in the amount of $305,000, payable in an initial installment of $25,000 on November 1, 2004 and monthly installments thereafter of $10,000 until the note is paid in full, and agreed to transfer to MonoGen certain assets. Inasmuch as the assets were not timely transferred, and because the initial $25,000 payment to be made under the note was not paid by its due date, MonoGen delivered a notice of default to the Company and AccuMed in November 2004. If the default asserted in the notice is not cured, there are a number of remedies that may be available to MonoGen under the provisions of the settlement agreement and the note, one of which is the possibility that the full principal amount of the note may be accelerated and declared immediately due and payable. To date, neither MDI nor any related party to the suit has received further notice in regard to the asserted default, although not all of the remedies that may be available to MonoGen in regard to such default would require that further notices be given. Ungaretti and Harris LLP. In March 2005, MDI entered into a settlement agreement related to a judgment entered against the Company and in favor of Ungaretti and Harris LLP in the law firm's suit against MDI for unpaid legal fees. In January 2005, the court had entered summary judgment in favor of Ungaretti & Harris in the amount of $195,500, plus costs of suit. The parties subsequently entered into a settlement agreement in satisfaction of the judgment, whereby MDI issued a note for $150,000 to the law firm, payable in installments of $25,000 commencing March 22, 2005, and with subsequent payments due in ninety day increments until the balance is paid in full. See Note 11 - Legal Proceedings for more information regarding the legal proceedings regarding or giving rise to the above Monsun, Ungaretti and Harris, and MonoGen notes. Defaults. Specific events of default have occurred on a significant majority of the outstanding notes payable issued by MDI, including the Bridge I and Bridge II convertible promissory notes, ranging from failure to make principal payments when due to breach of certain warranties and representations. The notes payable require the holder to notify MDI in writing of a declaration of default at which time a cure period, as specified in each individual note, would commence. There is no guarantee that MDI would be able to cure any event of default if, or when, the holder provides the required written notice. Other than the Monsun convertible promissory note, the MonoGen note payable, and the note payable to Ungaretti and Harris, which are the subject of legal actions described in Note 11 - Legal Proceedings (certain of which have been settled as discussed herein), MDI has not received any written declarations of default from holders of its outstanding notes payable. Carrying Amounts. Management believes it is not practicable to estimate the fair value of the notes payable due to the uncertainty regarding repayment or possible conversion and the Company's current financial condition. Note 8. Stockholders' Equity A summary of the Company's preferred stock capital table is as follows:
March 31, December 31, 2005 2004 ---- ---- Shares Issued & Shares Issued & Offering Outstanding Outstanding (unaudited) Series A convertible.............................................. 82,655 82,655 Series B convertible, 10% cumulative dividend..................... 365,106 365,106 Series C convertible, 10% cumulative dividend..................... 262,833 262,833 Series D convertible, 10% cumulative dividend..................... 175,000 175,000 Series E convertible, 10% cumulative dividend..................... 233,598 233,598 ----------- ----------- Total Preferred Stock...................................................... 1,119,192 1,119,192 =========== ===========
Summary of Preferred Stock Terms Series A Convertible Preferred Stock Liquidation Value: $4.50 per share Conversion Price: $10.3034 per share Conversion Rate: 0.4367--Liquidation Value divided by Conversion Price ($4.50/$10.3034) Voting Rights: None Dividends: None Conversion Period: Any time 13 Series B Convertible Preferred Stock Liquidation Value: $4.00 per share Conversion Price: $1.00 per share Conversion Rate: 4.00--Liquidation Value divided by Conversion Price ($4.00/$1.00) Voting Rights: None Dividends: 10%--Quarterly--Commencing March 31, 2001 Conversion Period: Any time Cumulative dividends in arrears at March 31, 2005 were $609,351 Series C Convertible Preferred Stock Liquidation Value: $3.00 per share Conversion Price: $0.60 per share Conversion Rate: 5.00--Liquidation Value divided by Conversion Price ($3.00/$0.60) Voting Rights: None Dividends: 10%--Quarterly--Commencing March 31, 2002 Conversion Period: Any time Cumulative dividends in arrears at March 31, 2005 were $269,117 Series D Convertible Preferred Stock Liquidation Value: $10.00 per share Conversion Price: $1.00 per share Conversion Rate: 10.00--Liquidation Value divided by Conversion Price ($10.00/$1.00) Voting Rights: None Dividends: 10%--Quarterly--Commencing April 30, 2002 Conversion Period:Any time Cumulative dividends in arrears at March 31, 2005 were $597,877 Series E Convertible Preferred Stock Liquidation Value: $22.00 per share Conversion Price: $0.80 per share Conversion Rate: 27.50--Liquidation Value divided by Conversion Price ($22.00/$0.80) Voting Rights: Equal in all respects to holders of common shares Dividends: 10%--Quarterly--Commencing May 31, 2002 Conversion Period:Any time Cumulative dividends in arrears at March 31, 2005 were $1,675,679 Issuance of Common Shares for Cash Beginning in December 2004, MDI began an offering of common stock to accredited investors in exchange for cash. As part of the offering, MDI granted each investor a warrant to purchase common stock at an exercise price of $0.10 per share, with the first $250,000 of investment to receive 50% warrant coverage and subsequent investments in excess of $250,000 to receive 25% coverage. In the first quarter of fiscal 2005, the Company had received net aggregate proceeds of $521,050 and issued an aggregate 9,608,334 shares of restricted common stock, as well as warrants to purchase 2,402,084 shares of common stock. MDI valued the warrants at $183,775 using the Black-Scholes valuation model and recorded the amount to additional paid-in-capital - warrants for the quarter ended March 31, 2005. Issuance of Warrants as a Settlement On July 18, 2003, Mr. Milley, a director of MDI, Azimuth Corporation (of which Mr. Milley is President and Chairman of the Board) and Cadmus Corporation (of which Mr. Milley is President), agreed to cancel seven warrants held by Azimuth and one warrant held by Cadmus, which warrants entitled the holders to purchase a total of 3,125,000 shares of MDI common stock at various exercise prices between $0.01 and $1.25 per share. The warrants, issued between December 14 1999 and August 2001, contained anti-dilution clauses which required MDI to increase the number of shares of common stock the holders were entitled to purchase under the warrants by approximately 1,500,000 shares as of the date of the agreement, with commensurate adjustments in individual exercise prices so that gross proceeds to the Company from exercise of the warrants remained the same. These anti-dilution provisions could have required the Company to make additional adjustments in shares and exercise prices in the future based on the Company's issuance of debt or equity instruments at prices below the adjusted exercise prices of these warrants. In consideration for the parties' agreement to cancel these warrants, including their individual anti-dilution clauses, and the forgiveness of approximately $100,000 owed to Azimuth and Cadmus, in February 2005 MDI issued warrants to purchase 2,875,000 and 3,625,000 shares to Azimuth and Cadmus, respectively, at an exercise price of $0.30 per share. MDI had also agreed to issue a 120-day warrant entitling the holders to purchase 500,000 shares of common stock at an exercise price of $0.30, which warrant expired on November 19, 2003. MDI valued the warrants at $420,551 using the Black-Scholes valuation model and recorded the amount as a current quarter administrative expense. Issuance of Warrants for Services In February 2005, MDI issued warrants to purchase 200,000 shares of common stock with an exercise price of $0.10 per share to a non-employee financial consultant for past financial services. MDI valued the warrants at $16,260 using the Black-Scholes valuation model and recorded the amount as a current quarter administrative expense. Application of Black-Scholes Valuation Model In applying the Black-Scholes valuation model, the Company has used an expected dividend yield of zero; a risk-free interest rate of 4.88% and 4.77% for the March 31, 2005 and 2004 periods, respectively; volatility factors of 146% and 182%, respectively; and a fair value of the underlying common shares of the closing market price on the date of the grant. The expected life equaled the term of the warrants, options, or restricted shares. Note 9. Equity Incentive Plan and Employee Stock Purchase Plan On May 25, 1999, stockholders approved the establishment of the 1999 Equity Incentive Plan (the "Plan") effective as of June 1, 1999. The Plan provides that the Board may grant various forms of equity incentives to directors, employees, and consultants, including but not limited to incentive stock options, non-qualified stock options, stock appreciation rights, and restricted stock awards. Awards under the Plan are exercisable at fair market value determined as of the date of grant in accordance with the terms of the Plan. Awards vest immediately or ratably over periods ranging from two to five years, and expire five to ten years from the date of grant. On May 23, 2000, stockholders approved Amendment No. 1 to the Plan, which increased the number of shares of common stock allocated for use in the Plan from 2,000,000 shares to 3,000,000 shares. On June 21, 2002, stockholders approved a second amendment to the Plan, which increased the number of shares allocated for use in the Plan from 3,000,000 shares to 5,500,000 shares. On July 29, 2004, stockholders approved a third amendment to the Plan, which increased the number of shares for use in the Plan from 5,500,000 to 20,000,000 shares. The Board of Directors has also granted options to purchase common stock of MDI outside of the Plan. As permitted by SFAS No. 123, MDI applies Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees" and related interpretations in accounting for options granted to employees under the Plan. No compensation cost was recorded during the first quarter of 2005 or 2004 for options granted to employees, as the exercise prices of such options approximated the fair value of the underlying common stock on the date of the grant. Had stock options been accounted for under the fair value method recommended by SFAS No. 123, the Company's net loss allocated to common shareholders would have been changed to the pro forma amounts indicated below: 15
For the three months ended March 31, 2005 2004 (in thousands except for per share amounts) Net loss applicable to common shareholders as reported............. $ (1,377) $ (2,360) Deduct: Total stock-based compensation determined under the fair value based method for all awards and forfeitures, net of related taxes.................................. (3) (158) ---------- ---------- Pro forma net loss applicable to common shareholders............... $ (1,380) $ (2,518) ========== ========== Basic and diluted loss per share applicable to common shareholders - as reported......................................... $ (0.01) $ (0.04) ========= ========== Basic and diluted loss per share applicable to common shareholders - pro forma.................................. $ (0.01) $ (0.05) ========= ==========
The fair value for these options was estimated at the date of the grant using a Black-Scholes option pricing model with the following weighted average assumptions: risk-free interest rates of 4.88% and 4.77% for the March 31, 2005 and 2004 periods, respectively; volatility factors of the expected market price of the Company's common stock of 146% and 182%, respectively; and a fair value of the underlying common shares of the closing market price on the date of the grant. The expected life equaled the term of the options or restricted shares. A summary of the Company's stock option activity and related information follows: Weighted Average Exercise Options Price Outstanding at January 1, 2004 . 3,494,648 Granted ........................ 2,500,000 $ 0.1540 Forfeited ...................... (1,046,921 $ 1.0276 ---------- Outstanding at December 31, 2004 4,947,727 Granted ...................... -- Forfeited ...................... (30,000) $ 0.9210 ---------- Outstanding at March 31, 2005 .. 4,917,727 ========== Exercisable at March 31, 2005 .. 3,591,061 $ 0.8450 ========== At the Annual Meeting on May 25, 1999, the stockholders also approved the Employee Stock Purchase Plan (the "ESPP"). The ESPP offers employees the opportunity to purchase shares of common stock of MDI through a payroll deduction plan at 85% of the fair market value of such shares at specified enrollment measurement dates. The aggregate number of shares available for purchase under the ESPP is 200,000. In December 2004, FASB issued Statement of Financial Accounting Standards No. 123(revised), "Share-Based Payment" ("SFAS No. 123(R)"). SFAS No. 123(R) establishes accounting standards for transactions in which a company exchanges its equity instruments for goods or services. In particular, this statement will require companies to record compensation expense for all share-based payments, such as employee stock options, at fair market value. This statement is effective for the Company as of the beginning of the first annual reporting period that begins after December 15, 2005. Adoption of this statement is not expected to have a material impact on the Company's consolidated financial position or results of operations. Note 10. Subsequent Events In April 2005, MDI, as part of its current common stock offering, offered common stock to accredited investors in exchange for cash. For the month ended April 30, 2005, the Company had received additional net proceeds of $117,000 and was obligated to issue 2,166,667 shares of restricted common stock and warrants to purchase an aggregate 541,667 shares of common stock at $0.10 per share in connection with such offering. Note 11. Legal Proceedings Settled in the First Quarter of Fiscal 2005 The Cleveland Clinic Foundation. On March 28, 2003, The Cleveland Clinic Foundation filed suit against MDI (U.S. District Court for the Northern District of Ohio, Eastern Division (Case No. 1:03CV0561)) seeking approximately $315,000 for certain clinical trial work conducted by the Foundation in the Peoples 16 Republic of China on behalf of MDI. On December 8, 2003, a default judgment in the amount of $260,000 was entered against MDI. In the first quarter of 2005, the parties agreed in principle to terms of settlement and are currently working on a definitive settlement agreement. MDI's last settlement payment is expected to be in July 2005, at which point it is expected that the default judgment will be deemed fully satisfied. Daniel Kussworm, Jennifer Kawaguchi, and Susan Keesee. On February 18, 2004, former MDI employees Daniel Kussworm, Jennifer Kawaguchi and Susan Keesee filed suit against MDI and one of its officers in the Circuit Court of Cook County, Illinois (04 L 1941) to recover wages and other compensation allegedly due them. These claims were settled and fully satisfied in January 2005, and the lawsuit has been dismissed. Ungaretti & Harris. On May 31, 2004, the law firm Ungaretti & Harris LLP filed an amended complaint against MDI in the Circuit Court of Cook County, Illinois (04 L 1101), to collect fees for services rendered prior to December 31, 2003. In January 2005, the court entered summary judgment in favor of Ungaretti & Harris LLP and against MDI in the amount of $195,500, plus costs of suit. The parties subsequently entered into a settlement agreement to satisfy the judgment. Under the agreement, MDI's payments to Ungaretti & Harris should conclude in 2006. Pending as of March 31, 2005 Hill & Barlow LLP. In February 2003, Hill & Barlow LLP, a now defunct law firm, filed a complaint against MDI in the Trial Court of the Commonwealth of Massachusetts (000740), seeking the collection of unpaid legal fees. Judgment was entered against MDI in the amount of $16,842, plus costs and interest. In April 2004, the parties entered into a settlement agreement. The terms of settlement have not been fully satisfied by the parties because a dispute has arisen concerning the return of MDI's files. Given that the law firm has dissolved, management does not expect a final resolution of this matter. Monsun. On January 9, 2003, Monsun, AS filed suit against Peter Gombrich, our former Chairman and CEO (U.S. District Court for the Northern District of Illinois, Eastern Division (Case No. 03 C 0184)), claiming $500,000 plus consequential damages for failure to make payment in compliance with the terms of a personal guaranty signed by Mr. Gombrich. The guaranty was executed in connection with Monsun's grant of an extension in the maturity date of a convertible promissory note issued by MDI on November 1, 2000 in favor of Monsun in the principal amount of $500,000. The note had an original maturity date of November 1, 2001. The maturity date of the note was initially extended until January 31, 2002 and subsequently to April 1, 2002 and finally to July 31, 2002. Monsun granted the final maturity date extension in exchange for the guaranty and various warrants issued by MDI entitling the holder to purchase shares of its common stock at various prices. In November 2002, the Board of Directors approved the issuance of 200,000 shares of common stock to Monsun to satisfy a default penalty clause in the guaranty. The terms of the guaranty required that Monsun receive registered shares of our common stock; however, in order to comply with securities laws, MDI issued the shares of common stock to Monsun with a restrictive legend, which permits their sale only in compliance with Rule 144 of the Securities Act of 1933, as amended. MDI recorded the principal amount of the note plus accrued and unpaid interest to December 31, 2003 as a note payable on its records. In March 2004, Monsun obtained a judgment against Mr. Gombrich in the amount of $675,199. In July 2004, Monsun obtained a second judgment against Mr. Gombrich in the amount of $438,419 for attorney fees and costs incurred in enforcing the guaranty agreement. Those judgments remain unsatisfied. Monsun has not filed suit directly against MDI to recover any amounts due under the note or otherwise. The Lash Group, Inc. On June 10, 2004, The Lash Group, Inc., a healthcare consulting firm, filed a lawsuit against the Company in the General Court of Justice, Superior Court Division, in Mecklenburg County, North Carolina (04 CVS 10367). The Lash Group seeks approximately $94,000, plus interest, attorney fees, and court costs, for the alleged breach of an agreement, with respect to which Peter Gombrich, our former Chairman and CEO, and MDI are sought to be held primarily liable. This action remains unresolved and the Company intends to contest the claims. Medical College of Georgia Research Institute, Inc. On November 18, 2003, the Medical College of Georgia Research Institute, Inc. filed suit against MDI in the Superior Court of Richmond County, Georgia (Case No. 2003-RCCV-1211) to collect amounts allegedly due pursuant to an agreement to provide a clinical study for MDI. Georgia Research Institute claimed that the principal amount of the obligation due from MDI was approximately $86,700, but sought to collect approximately $315,300 pursuant to an interest provision of 10% per month. On 17 October 27, 2004, the court entered summary judgment in favor of Georgia Research Institute and against MDI in the amount of $68,404. MDI expects to propose terms of settlement to satisfy this judgment in 2005. Eric Gombrich. On May 19, 2004, former employee Eric Gombrich filed suit against MDI in the Circuit Court of Cook County, Illinois (04 L 5661). Mr. Gombrich claims that MDI breached a written employment contract and that it owes him $631,258 (plus interest) and 300,000 shares of MDI stock. Although MDI made initial attempts to resolve this dispute, it is currently contesting Mr. Gombrich's action. The Regents of the University of California. On May 28, 2004, The Regents of the University of California filed suit against MDI in the Superior Court of California, County of San Francisco (CGC-04-431944). The University of California claims that MDI breached an agreement to sponsor a research project for a period of one year. The complaint seeks compensatory damages in the amount of $57,530 and an additional lost opportunity damages in the amount of $75,220. In January 2005, the University of California requested that the court enter a default judgment against MDI in the amount of $132,827, which includes court costs. The parties are currently involved in settlement negotiations with respect to this matter. Arthur Lipper III. On July 8, 2004, Arthur Lipper III filed a lawsuit against MDI in the Circuit Court of Cook County, Illinois (04 L 7671). Mr. Lipper claims that MDI breached a consulting services agreement and seeks $60,000, plus interest and court costs. MDI is contesting this claim. Kanan, Corbin, Schupak & Aronow, Inc. On August 12, 2004, Kanan, Corbin, Schupak & Aronow, Inc. ("KCSA") filed suit against AccuMed International, Inc. f/d/b/a Molecular Diagnostics, Inc. in the Circuit Court of Cook County, Illinois (04 L 9109), seeking $59,678, plus interest and court costs, for services provided. MDI has not yet been formally served with the summons and complaint in this case. Reid Jilek. On October 20, 2004, Reid Jilek filed a lawsuit against MDI in the Circuit Court of Cook County, Illinois (04 CH 17375). Mr. Jilek claims that MDI breached a 2003 services agreement and that MDI subsequently breached a 2004 settlement agreement. Mr. Jilek seeks $180,000 pursuant to the services agreement, or alternatively, seeks $114,000 pursuant to the settlement agreement. Mr. Jilek also seeks a court order that MDI issue to him 1,500,000 warrants to purchase MDI stock at $0.17 per share, pursuant to the services agreement. MDI previously issued to Mr. Jilek warrants to purchase an aggregate 1 million shares of its common stock, and intends to contest Mr. Jilek's claims. Esoterix, Inc. Esoterix, Inc. made a claim against MDI for $19,725, arising from a laboratory services agreement that it maintains MDI breached. In March 2005, Esoterix filed suit against MDI to pursue this claim in the Circuit Court of Cook County, Illinois (05 M1 116482). MDI is currently engaged in settlement discussions with Esoterix. Peter Gombrich. On April 25, 2005, former MDI officer Peter Gombrich filed suit against MDI in the Circuit Court of Cook County, Illinois (05 L 4543). Mr. Gombrich claims that MDI breached a written employment contract and that it owes him in excess of $849,500 (plus interest and attorneys' fees). Mr. Gombrich also alleged a claim against MDI for contribution and indemnification regarding agreements he signed as a guarantor for certain alleged MDI obligations. MDI has not yet responded to the complaint. Miscellaneous MonoGen, Inc. In July 2002, MonoGen, Inc. initiated an arbitration proceeding against the Company and its subsidiaries, AccuMed and Oncometrics Imaging Corp. (collectively, the "MDI Group"), alleging that the MDI Group had violated MonoGen's rights under certain license agreements (the "License Agreements") separately entered into by the subsidiaries with MonoGen prior to the Company's acquisition of the subsidiaries. In December 2002, the parties to the arbitration entered into an agreement (the "Technology Agreement") that purported to settle the issues that had been raised in the arbitration complaint. However, the Technology Agreement did not have the desired effect of ending the dispute, and in May 2003 the MDI Group filed suit in the Circuit Court of Cook County, Illinois (the "State Court Case") against MonoGen and two individuals affiliated with MonoGen in an attempt to obtain a judicial resolution of the issues that had been raised in the arbitration. The State Court Case also sought to resolve certain allegations of breach of fiduciary 18 duties made by the Company against the President of MonoGen, Norman Pressman, who had been the President of both AccuMed and Oncometrics at the time the License Agreements had been entered into by the parties. MonoGen resisted the State Court Case by, among other things, insisting that the dispute could only be settled in arbitration, as required in the License Agreements. The claim as to MonoGen was dismissed on that basis. MonoGen subsequently filed amended demands against the MDI Group in the arbitration proceeding, which had never been dismissed. In order to avoid unnecessary litigation expenses, in February 2004, the MDI Group agreed to a dismissal of the State Court Case, leaving the arbitration proceeding as the principal venue for a resolution of the dispute over the license rights obtained by MonoGen from the Company's subsidiaries. In October 2004, the parties to the arbitration attempted to settle most of the claims brought in that proceeding by virtue of a proposed settlement agreement that provided for the Company and AccuMed to, among other things, transfer certain patents, patent applications and other intellectual property rights, as well as certain identified AcCell units and spare parts, to MonoGen, and to simultaneously issue to MonoGen a joint unsecured installment promissory note in the principal amount of $305,000. The note called for an initial payment of $25,000 to be made by the Company and AccuMed to MonoGen on November 1, 2004, with subsequent monthly payments of $10,000 each to be made until the full principal balance has been paid. The settlement agreement also provided for the termination of the License Agreements and the Technology Agreement, but reserved all rights of the parties in regard to any matters that may continue to be disputed among them and the British Columbia Cancer Agency arising out of, or related to, the License Agreement between Oncometrics and MonoGen. In as much as the AcCell units and spare parts were not transferred to MonoGen within the time period prescribed in the settlement agreement, and because the initial $25,000 payment to be made under the note was not paid by its due date, MonoGen delivered a notice of default to the Company and AccuMed in November 2004. If the default asserted in the notice is not cured, there are a number of remedies that may be available to MonoGen under the provisions of the settlement agreement and the note, one of which is the possibility that the full principal amount of the note may be accelerated and declared immediately due and payable. To date, no member of the MDI Group has received further notice in regard to the asserted default, although not all of the remedies that may be available to MonoGen in regard to such default would require that further notices be given. Other Creditors; Wage and Related Claims. MDI is a defendant in several lawsuits brought by current or former unsecured creditors to collect past due amounts for goods and services. MDI has recorded the amounts due in its records and is attempting to settle these suits and unfiled claims. MDI is also currently negotiating the settlement of wage claims brought by former employees seeking to collect for unpaid wages and severance benefits. MDI has recorded the amounts due in its records and is attempting to settle these claims. MDI does not consider any of these claims to be material. Ketchum Public Relations. In June 2004, MDI settled a $72,000 claim made by Ketchum Public Relations. No litigation was ever filed by Ketchum. It is expected that MDI's monthly settlement payments to Ketchum will conclude in 2005. Item 2. Management's Discussion and Analysis or Plan of Operation Forward-Looking Statements Certain statements contained in this discussion and analysis that are not related to historical results are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are predictive, that depend upon or refer to future events or conditions, or that include words such as "expects," "anticipates," "intends," "plans," "believes," "estimates," "hopes," and similar expressions constitute forward-looking statements. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), business strategies or prospects, or possible future actions by us are also forward-looking statements. These forward-looking statements are based on beliefs of our management as well as current expectations, projections and assumptions currently available to the Company and are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or those anticipated or implied by such forward-looking statements. These risks are described more 19 fully in our most recent Annual Report on Form 10-KSB for the fiscal year ended December 31, 2004 under the caption "Risk Factors" and in subsequent reports filed with the Securities and Exchange Commission. Should one or more of those risks or uncertainties materialize or should underlying expectations, projections and assumptions prove incorrect, actual results may vary materially from those described. Those events and uncertainties are difficult to predict accurately and many are beyond our control. We assume no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date of these statements except as specifically required by law. Accordingly, past results and trends should not be used to anticipate future results or trends. Overview of Molecular Diagnostics, Inc. Molecular Diagnostics, Inc., formerly Ampersand Medical Corporation, is a biomolecular diagnostics company engaged in the design, development and commercialization of cost-effective screening systems to assist in the early detection of cancer. MDI is currently focused on the design, development and marketing of its InPath(TM) System and related image analysis systems. The InPath System and related products are intended to detect cancer and cancer-related diseases, and may be used in a laboratory, clinic or doctor's office. The science of medical diagnostics has advanced significantly during the past decade. Much of this advance has come as a result of new knowledge of the human genome and related proteins, which form the foundation of cell biology and the human body. Our goal is to utilize this research as a base to develop screening and diagnostic testing products for cancer and cancer-related diseases. We believe that the success of these products will improve patient care through more accurate test performance, wider product availability and more cost effective service delivery. We are developing an initial series of products to address these criteria including sample collection devices, chemical and biological tests, and analysis instruments and related software. Our strategy is to develop products through internal development processes, strategic partnerships, licenses and acquisitions of companies. This strategy has required and will continue to require additional capital. As a result, we will incur substantial operating losses until we are able to successfully market some, or all, of our products. We have designed and manufactured the AcCell(TM) computer-aided automated microscopy instrument and the AcCell Savant(TM), an instrument that includes an AcCell instrument and software and which collects quantitative cellular information used in support of a diagnostic process. These instruments have been sold to laboratories and medical diagnostic companies for use in the customers' proprietary applications, although based on a settlement entered into with MonoGen, Inc. in 2004, we have transferred certain patents and intellectual property rights for the AcCell instrument to MonoGen. MDI also entered into to a settlement agreement with Dr. Bruce Patterson and Invirion, Inc. over the validity of a certain technology license. MDI agreed to the termination and return of the license to Dr. Patterson and Invirion. The Company now is focused on marketing a new, fully-integrated workstation - the Automated Image Proteomic System or "AIPS(TM)" - based on updated technology. We expect that the new platform will be marketed through a distribution partner and, in certain instances, will be placed in a customers' facility on a fee-for-use basis. Nearly all of our reported revenue to date has been from the sale of AcCell products and services and from a former subsidiary's discontinued operations. The Company has incurred significant operating losses since its inception. Management expects that significant on-going operating expenditures will be necessary to successfully implement MDI's business plan and develop, manufacture and market its products. These circumstances raise substantial doubt about MDI's ability to continue as a going concern. Implementation of the Company's plans and its ability to continue as a going concern depend upon its securing substantial additional financing. During the first three months of 2005, MDI raised net proceeds of $521,050 through the sale of common stock. Management's plans include substantial efforts to obtain additional capital. If the Company is unable to obtain adequate additional financing or generate profitable sales revenues, it may be required to curtail its product development and other activities and may be forced to cease operations. Critical Accounting Policies and Changes to Accounting Policies The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and 20 liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. There have been no material changes in our critical accounting policies or critical accounting estimates since December 31, 2004, nor have we adopted any accounting policy that has or will have a material impact on our consolidated financial statements. For further discussion of our accounting policies see Note 3 - Summary of Significant Accounting Policies in the Notes to Consolidated Financial Statements included in this Quarterly Report on Form 10-QSB, as well as our Annual Report on Form 10-KSB for the fiscal year ended December 31, 2004. Results of Operations The following discussion and analysis should be read in conjunction with our unaudited consolidated financial statements presented in Part I, Item 1 of this Quarterly Report and our audited consolidated financial statements and notes thereto, as well as our Management's Discussion and Analysis, contained in our Annual Report on Form 10-KSB for the year ended December 31, 2004 as filed with the SEC. Three Months Ended March 31, 2005 as compared to Three Months Ended March 31, 2004 Revenue Revenues for the three months ended March 31, 2005 decreased $13,000, or 24.5%, to $40,000 from revenues of $53,000 for the same period in 2004. This decrease was the result of a reduction in revenue from the sale of our slide-based installed systems. Costs and Expenses Cost of Goods Sold Cost of goods sold was zero for the quarters ended March 31, 2005 and March 31, 2004, respectively. Research and Development We devote a substantial amount of our resources to research and development ("R&D") related to new products, including markers, tests, instruments and software applications, as well as modifications to and refinements of our existing products. For the quarter ended March 31, 2005, our R&D expenses were $72,000, a decrease of $85,000, or 54.1%, over the same period in 2004. This decrease was the result of reduced operating capacity due to capital and liquidity constraints. This reduction has led to delays in the finalization of development, completion of clinical trial validation, Food and Drug Administration submissions, market introduction, and the sale of some of our products. R&D expenses typically consist of costs related to specific development programs with scientists and researchers at universities and hospitals; full scale device development contracts begun during 1999 with industrial design and manufacturing companies covering the disposable and instrument components of the InPath System; payments to medical and engineering consultants for advice related to the design and development of our products and their potential uses in the medical technology marketplace; and payroll related costs for in-house engineering, scientific, laboratory, software development and research management staff. Selling, General and Administrative For the quarter ended March 31, 2005, selling, general and administrative expenses ("SG&A") were $717,000, a decrease of $698,000, or 49.3%, over expenses of $1,415,000 for the same period in 2004. This decrease included a reduction of $406,000 in financing costs, $67,000 in investor relations expenditures, $94,000 in other general and administrative costs and $131,000 in legal and professional fees. Significant components of SG&A are compensation costs for executive, sales and administrative personnel; professional fees primarily related to legal and 21 accounting services; travel costs; fees for public and/or investor relations services; insurance premiums; facilities and office expenses; marketing-related costs; and amortization/depreciation charges. Other Income and Expense Interest Expense Interest expense, including interest expense to related parties, decreased $297,000 for the first quarter ended March 31, 2005 to $403,000, a decrease of 42.4% over the same period of 2004. Bridge I, II, III, IV, and related party convertible promissory notes in principal amounts totaled $6,356,000 and $5,297,000 for the fiscal quarters ended March 31, 2005 and 2004, respectively. The change included an decrease in interest expense of $10,000 related to the lower interest rates on the Bridge III and IV notes and a decrease of $289,000 related to the amortization of debt discount arising from the beneficial conversion feature of certain of the notes. The amortized debt discount amount decreased due to an increase in the duration of the new Bridge III and IV notes issued during 2004 in relation to the shorter maturity periods of the Bridge I and II notes issued during 2001 through 2003. Restructuring Settlements For the quarter ended March 31, 2005, MDI did not record any restructuring settlements, a decrease of $161,000 or 100% over the same period in 2004. The gain recorded during the quarter ended March 31, 2004 resulted from the settlement of various litigation and credit payment matters during that period. Net Loss The net loss for the three-month period ended March 31, 2005 before preferred dividends totaled $1,152,000, compared with $2,048,000 for the same period in 2004, a decrease of $896,000 or 43.8%. The decrease was primarily the result of reduced operating capacity due to capital and liquidity constraints as well as a reduction in interest expense. In addition, cumulative dividends on the Company's outstanding Series B, Series C, Series D and Series E convertible preferred stock totaled $225,000 for the quarter ended March 31, 2005, compared with $312,000 for the same period in 2004. The net loss applicable to common stockholders for the three months ended March 31, 2005 was $1,377,000, or $0.01 per share, on 104,343,116 weighted average common shares outstanding. This compared with the net loss applicable to common stockholders for the three-month period ended March 31, 2004 of $2,360,000, or $0.04 per share, on 55,812,649 weighted average common shares outstanding. Liquidity and Capital Resources Research and development, clinical trials and other studies of the components of our InPath System, conversions from designs and prototypes into product manufacturing, initial sales and marketing efforts, medical consultants and advisors, and research, administrative, and executive personnel are and will continue to be the principal basis for our cash requirements. We have provided operating funds for the business since its inception through private offerings of debt and equity to limited numbers of U.S. and foreign accredited investors. We will be required to make additional offerings in the future to support the operations of the business until some or all of our products are introduced into the market. We used $525,000 and $1,216,000 for the first quarter ended March 31, 2005 and 2004, respectively, in operating activities. We experienced severe liquidity problems during the quarter ended March 31, 2005. As a result, we were forced to cut staff and reduce our operations to a minimum level. Officers refrained from drawing salaries during portions of the first quarter of 2005 in order to reduce demands on our limited cash position. We were able to raise funds through the sale of common stock during the quarter, although the proceeds of the common stock offerings were used to satisfy certain obligations coming due at that time as well as for the payment of a limited amount of current operational expenses. At March 31, 2005, we had $3,000 cash on hand, a decrease of $8,000 over cash on hand at December 31, 2004 of $11,000. This cash position results from our loss from operations and our inability to raise sufficient new capital due to very unfavorable conditions in financing markets, both public and private, for companies in general, and especially for small life sciences companies such as ours. We were unable to raise sufficient funds during the quarter to maintain adequate cash reserves and to meet the ongoing operational needs of the business. 22 We incurred no capital expenditures during the first quarter of 2005 versus capital expenditures of $29,000 for the first quarter 2004, a decrease of 100%. Capital expenditures are defined as disbursements for laboratory equipment, leasehold improvements, software, and furniture/fixtures with a purchase price in excess of $1,000 per item and useful life in excess of one year. MDI is striving to keep capital expenditures to a minimum due to capital and liquidity constraints, and the Company has no plans for material commitments for capital expenditures in the near-term. Our operations have been, and will continue to be, dependent upon management's ability to raise operating capital in the form of debt or equity. We have incurred significant operating losses since inception of the business. We expect that significant on-going operating expenditures will be necessary to successfully implement our business plan and develop, manufacture and market our products. These circumstances raise substantial doubt about our ability to continue as a going concern. There can be no assurance that we will be able to obtain additional capital to meet our current operating needs or to complete pending or contemplated licenses or acquisitions of technologies. If we are unable to raise sufficient adequate additional capital or generate profitable sales revenues, we may be forced to substantially curtail product research and development and other activities and may be forced to cease operations. Off-Balance Sheet Arrangements The Company does not have any off-balance sheet arrangements. Item 3. Controls and Procedures Evaluation of Disclosure Controls and Procedures Our chief executive officer and chief financial officer have reviewed and evaluated the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) as of the end of the period covered by this quarterly report. Based on that review and evaluation, our chief executive officer and chief financial officer have concluded that our current disclosure controls and procedures, as designed and implemented, are reasonably adequate to ensure that such officers are provided with information relating to the Company required to be disclosed in the reports filed or submitted by MDI under the Exchange Act and that such information is recorded, processed, summarized and reported within the time periods specified. Changes in Internal Control over Financial Reporting During the quarter to which this report relates, there was no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Part II. Other Information Item 1. Legal Proceedings See Note 11 - Legal Proceedings in the Notes to Consolidated Financial Statements included herein for a discussion of the most recent events regarding the Company's pending and threatened legal proceedings, which information is incorporated herein by reference. Item 2. Unregistered Sales of Equity Securities and Use of Proceeds Unregistered Sales of Equity Securities Common Stock. Beginning in December 2004, MDI began an offering of common stock to accredited investors in exchange for cash. As part of the offering, MDI granted each investor a warrant to purchase common stock at an exercise price of $0.10 per share, with the first $250,000 of investment to receive 50% warrant coverage and subsequent investments in excess of $250,000 to receive 25% coverage. In the first quarter of fiscal 2005, the Company had received net aggregate proceeds of $521,050 and issued an aggregate 9,608,334 shares of restricted common stock, as well as warrants to purchase 2,402,084 shares of common stock. MDI valued the warrants at $183,775 using the Black-Scholes valuation model and recorded the amount as to additional paid-in-capital - warrants for the quarter ended March 31, 2005. 23 Warrants. In February 2005, MDI issued warrants to purchase an aggregate 6,500,000 shares of common stock of the Company with an exercise price of $0.30 per share to Azimuth Corporation and Cadmus Corporation in exchange for such warrant holders' agreement to cancel certain other warrants containing anti-dilution provisions unfavorable to the Company. MDI valued the warrants at $420,551 using the Black-Scholes valuation model and recorded the amount as an administrative expense in the first quarter ended March 31, 2005. In February 2005, MDI issued warrants to purchase 200,000 shares of common stock of the Company with an exercise price of $0.10 per share to a non-employee financial consultant for past financial services. MDI valued the warrants at $420,551 using the Black-Scholes valuation model and recorded the amount as an administrative expense in the first quarter ended March 31, 2005. MDI issues securities in reliance on the safe harbor and exemptions from registration provided under Rule 506 of Regulation D and/or Section 4(2) of the Securities Act of 1933, as amended. No advertising or general solicitation was employed in offering the securities. The offerings and sales or issuances were made to a limited number of persons, all of whom were accredited investors, and transfer was restricted by the Company in accordance with the requirements of applicable law. In addition to representations by the above-referenced persons, the Company has made independent determinations that all of the investors were accredited or sophisticated investors, that they were capable of analyzing the merits and risks of their investment, and that they understood the speculative nature of their investment. Furthermore, these investors were provided with access to MDI's SEC filings. Warrants issued by the Company during the quarter expire five years from the date of issuance and are exercisable immediately upon issuance. None of the warrants are subject to any vesting schedules or conditions other than those imposed by applicable securities laws. The exercise price and number of shares issuable upon exercise of such warrants are subject to anti-dilution protection in the event the Company effects a subdivision or combination of its common stock or declares or pays a dividend or distribution in common stock; the warrants also provide for adjustments in the event the Company declares or pays a dividend or other distribution in other securities or property of the Company or is a party to a reorganization, reclassification, merger or similar event. Company Repurchases of Securities During the first quarter of fiscal 2005, neither the Company nor any affiliated purchaser of the Company purchased equity securities of MDI. Item 3. Defaults upon Senior Securities As of March 31, 2005, MDI had failed to make the required principal and interest payments, constituting events of default, on the following notes payable: o $750,000 in Bridge I convertible promissory notes; o $1,300,000 in Bridge II convertible promissory notes; o $822,000 Monsun AS convertible promissory note; o $149,000 Ungaretti & Harris LLP secured promissory note; o $31,000 Ernst & Young LLP promissory note; o $305,000 MonoGen, Inc. promissory note and; o $21,000 Ventana Medical Systems, Inc. promissory note The notes payable require the holder to notify MDI in writing of a declaration of default at which time a cure period, as specified in each individual note, would commence. There is no guarantee that MDI would be able to cure any event of default if, or when, the holder provides the required written notice. Other than the Monsun AS convertible promissory note, the MonoGen note payable, and the note payable to Ungaretti & Harris, which are the subject of legal actions referred to in Part II, Item 1 above and in Note 11 - Legal Proceedings in the Notes to Consolidated Financial Statements included herein (certain of which have been settled as described herein), MDI has not received any written declarations of default from holders of outstanding notes payable. 24 Item 4. Submission of Matters to Vote of Security Holders None Item 5. Other Information None Item 6. Exhibits K See Exhibit Index 25 SIGNATURES In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Molecular Diagnostics, Inc. /s/ Denis M. O'Donnell, M.D. --------------------------------------- Denis M. O'Donnell, M.D. Chief Executive Officer and President /s/ Dennis L. Bergquist --------------------------------------- Dennis L. Bergquist Chief Financial Officer Date: May 19, 2005 26 EXHIBIT INDEX Exhibit Number Description 4.1 Form of common stock purchase warrant issued to financial consultant on February 15, 2005 representing the right to purchase 200,000 shares of common stock of the Company. 31.1 Section 302 certification by principal executive officer. 31.2 Section 302 certification by principal financial officer. 32.1 Section 906 certification by principal executive officer. 32.2 Section 906 certification by principal financial officer. 27 EX-4.1 2 v018881_ex4-1.txt THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT") OR APPLICABLE STATE SECURITIES LAWS, AND ARE "RESTRICTED SECURITIES" AS THAT TERM IS DEFINED IN RULE 144 UNDER THE ACT. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS, OR PURSUANT TO AN EXEMPTION FROM REGISTRATION THEREFROM, THE AVAILABILITY OF WHICH IS TO BE ESTABLISHED TO THE SATISFACTION OF MOLECULAR DIAGNOSTICS, INC. Warrant No.MP1 WARRANT TO PURCHASE SHARES OF COMMON STOCK ISSUE DATE: February 15, 2005 This certifies that Michael Pisani, or any valid transferee thereof (the "Holder"), for value received, is entitled to purchase from Molecular Diagnostics, Inc., a Delaware corporation with its principal business office located at 414 North Orleans Street, Suite 502, Chicago, Illinois 60610 (the "Company"), subject to the terms and conditions set forth below, at any time or from time to time on and after the Vesting Date (as defined below) set forth above and before 3:00 p.m. (Central Time) on the fifth anniversary of the Vesting Date (the "Expiration Date"), 200,000 shares of Common Stock, $.001 par value per share, of the Company ("Common Stock"), at a purchase price of $0.10 per share. The shares purchasable upon exercise of this Warrant, and the purchase price per share, each as adjusted from time to time pursuant to the provisions of this Warrant, are hereinafter referred to as the "Warrant Shares" and the "Purchase Price," respectively. As consideration for this Warrant, the Holder named above agrees to forgive all outstanding indebtedness of the Company to such named Holder. The Holder expressly agrees and acknowledges that this Warrant shall not vest, and shall not be exercisable, in whole or in part, until such time as the stockholders of the Company approve an increase in the number of authorized shares of Common Stock of the Company and an amendment to the Company's Certificate of Incorporation is filed with the Secretary of State of the State of Delaware to effect such increase (such date, the "Vesting Date"). 1. Exercise. (a) Exercise for Cash. The Holder may, at the Holder's option, elect to exercise this Warrant, in whole or in part and at any time or from time to time on or after the Vesting Date but prior to 3:00 p.m. (Central Time) on the Expiration Date, by surrendering this Warrant, with the purchase form appended hereto as Exhibit I duly executed by or on behalf of the Holder, at the principal office of the Company, or at such other office or agency as the Company may designate, accompanied by payment in full, in lawful money of the United States, of the Purchase Price payable in respect of the number of Warrant Shares purchased upon such exercise. In no event shall any such exercise be for fewer than 10,000 Warrant Shares unless fewer than an aggregate of 10,000 Warrant Shares are then purchasable under all outstanding Warrants held by the Holder. Payment of the aggregate Purchase Price may be made in cash, certified or bank check, or wire transfer of immediately available funds. (b) Cashless Exercise. (i) The Holder may, at the Holder's option, elect to exercise this Warrant, in whole or in part and at any time or from time to time on or after the Vesting Date but prior to 3:00 p.m. (Central Time) on the Expiration Date, on a cashless basis, by surrendering this Warrant, with the purchase form appended hereto as Exhibit I duly executed by or on behalf of the Holder, at the principal office of the Company, or at such other office or agency as the Company may designate, by canceling a portion of this Warrant in payment of the Purchase Price payable in respect of the number of Warrant Shares purchased upon such exercise. In the event of an exercise pursuant to this subsection 1(b), the number of Warrant Shares issued to the Holder shall be determined according to the following formula: X = Y(A-B) ------ A Where: X = the number of Warrant Shares that shall be issued to the Holder; Y = the number of Warrant Shares for which this Warrant is being exercised (which shall include both the number of Warrant Shares issued to the Holder and the number of Warrant Shares subject to the portion of the Warrant being cancelled in payment of the Purchase Price); A = the Fair Market Value (as defined below) of one share of Common Stock; and B = the Purchase Price then in effect. (ii) The Fair Market Value per share of Common Stock shall be determined as follows: (1) If the Common Stock is listed on a national securities exchange, the Nasdaq National Market or the Nasdaq SmallCap Market, or another nationally recognized trading system as of the Exercise Date (as defined in (c) below), the Fair Market Value per share of Common Stock shall be deemed to be the average of the highest and lowest reported sale prices per share of Common Stock thereon on the trading day immediately preceding the Exercise Date ; provided that if no such price is reported on such day, the Fair Market Value per share of Common Stock shall be determined pursuant to clause (3). (2) If the Common Stock is not listed on a national securities exchange, the Nasdaq National Market or the Nasdaq SmallCap Market, or another nationally recognized trading system as of the Exercise Date, but is quoted on the Over-The-Counter Bulletin Board, the Fair Market Value per share of Common Stock shall be deemed to be the average of the highest bid and lowest asked prices quoted thereon on the trading day immediately preceding the Exercise Date; provided that if no price is reported on such day, the Fair Market Value per share of Common Stock shall be determined pursuant to clause (3). -2- (3) If the Common Stock is not listed on a national securities exchange, the Nasdaq National Market, the Nasdaq SmallCap Market or another nationally recognized trading system or the Over-the-Counter Electronic Bulletin Board as of the Exercise Date, the Fair Market Value per share of Common Stock shall be deemed to be the amount most recently determined by the Board of Directors of the Company (the "Board") to represent the fair market value per share of the Common Stock (including without limitation a determination for purposes of granting Common Stock options or issuing Common Stock under any plan, agreement or arrangement with employees of the Company); and, upon request of the Holder, the Board (or a representative thereof) shall, as promptly as reasonably practicable but in any event not later than 10 business days after such request, notify the Holder of the Fair Market Value per share of Common Stock. Notwithstanding the foregoing, if the Board has not made such a determination within the three-month period prior to the Exercise Date, then (A) the Board shall make, and shall provide or cause to be provided to the Holder notice of, a determination of the Fair Market Value per share of the Common Stock within 15 business days of a request by the Holder that it do so, and (B) the exercise of this Warrant pursuant to this subsection 1(b) shall be delayed until such determination is made and notice thereof is provided to the Holder. (c) Exercise Date and Status as Holder of Shares. Each exercise of this Warrant shall be deemed to have been effected immediately prior to the close of business on the day on which this Warrant shall have been surrendered to the Company as provided in subsection 1(a) or 1(b) above (the "Exercise Date"), which Exercise Date(s) shall not be prior to the Vesting Date. At such time, the person or persons in whose name or names any certificates for Warrant Shares shall be issuable upon such exercise as provided in subsection 1(d) below shall be deemed to have become the holder or holders of record of the Warrant Shares represented by such certificates. (d) Issuance of Certificates. As soon as practicable after the exercise of this Warrant in whole or in part, and in any event within 10 business days thereafter, the Company, at its expense, will cause to be issued in the name of, and delivered to, the Holder, or as the Holder (upon payment by the Holder of any applicable transfer taxes) may direct: (i) a certificate or certificates for the number of full Warrant Shares to which the Holder shall be entitled upon such exercise plus, in lieu of any fractional share to which the Holder would otherwise be entitled, cash in an amount determined pursuant to Section 3 hereof; and (ii) in case such exercise is in part only, a new warrant or warrants (dated the date hereof) of like tenor, calling in the aggregate on the face or faces thereof for the number of Warrant Shares equal (without giving effect to any adjustment therein) to the number of such shares called for on the face of this Warrant minus the number of Warrant Shares for which this Warrant was so exercised (which, in the case of an exercise pursuant to subsection 1(b), shall include both the number of Warrant Shares issued to the Holder pursuant to such partial exercise and the number of Warrant Shares subject to the portion of the Warrant being cancelled in payment of the Purchase Price). -3- (e) Warrant Shares. The Warrant Shares issued upon any such exercise of this Warrant shall be validly issued, fully paid and non-assessable. 2. Adjustments. (a) Adjustment for Stock Splits and Combinations. If the Company shall at any time or from time to time after the Issue Date as set forth on the first page hereof (or, if this Warrant was issued upon partial exercise of, or in replacement of, another warrant of like tenor, then the date on which such original warrant was first issued) (either such date being referred to as the "Original Issue Date") effect a subdivision of the outstanding Common Stock, the Purchase Price then in effect immediately before that subdivision shall be proportionately decreased. If the Company shall at any time or from time to time after the Original Issue Date combine the outstanding shares of Common Stock, the Purchase Price then in effect immediately before the combination shall be proportionately increased. Any adjustment under this paragraph shall become effective at the close of business on the date the subdivision or combination becomes effective. (b) Adjustment for Certain Dividends and Distributions. In the event the Company at any time or from time to time after the Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable in additional shares of Common Stock, then and in each such event the Purchase Price then in effect immediately before such event shall be decreased as of the time of such issuance or, in the event such a record date shall have been fixed, as of the close of business on such record date, by multiplying the Purchase Price then in effect by a fraction: (1) the numerator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date, and (2) the denominator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date plus the number of shares of Common Stock issuable in payment of such dividend or distribution; provided, however, that if such record date shall have been fixed and such dividend is not fully paid or if such distribution is not fully made on the date fixed therefor, the Purchase Price shall be recomputed accordingly as of the close of business on such record date and thereafter the Purchase Price shall be adjusted pursuant to this paragraph as of the time of actual payment of such dividends or distributions. (c) Adjustment in Number of Warrant Shares. When any adjustment is required to be made in the Purchase Price pursuant to subsections 2(a) or 2(b), the number of Warrant Shares purchasable upon the exercise of this Warrant shall be changed to the number determined by dividing (i) an amount equal to the number of shares issuable upon the exercise of this Warrant immediately prior to such adjustment, multiplied by the Purchase Price in effect immediately prior to such adjustment, by (ii) the Purchase Price in effect immediately after such adjustment. -4- (d) Adjustments for Other Dividends and Distributions. In the event the Company at any time or from time to time after the Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable in securities of the Company (other than shares of Common Stock) or in cash or other property (other than regular cash dividends paid out of earnings or earned surplus, determined in accordance with generally accepted accounting principles), then and in each such event provision shall be made so that the Holder shall receive upon exercise hereof, in addition to the number of shares of Common Stock issuable hereunder, the kind and amount of securities of the Company, cash or other property which the Holder would have been entitled to receive had this Warrant been exercised on the date of such event and had the Holder thereafter, during the period from the date of such event to and including the Exercise Date, retained any such securities receivable during such period, giving application to all adjustments called for during such period under this Section 2 with respect to the rights of the Holder. (e) Adjustment for Reorganization. If there shall occur any reorganization, recapitalization, reclassification, consolidation or merger involving the Company in which the Common Stock is converted into or exchanged for securities, cash or other property (other than a transaction covered by subsections 2(a), 2(b) or 2(d)) (collectively, a "Reorganization"), then, following such Reorganization, the Holder shall receive upon exercise hereof the kind and amount of securities, cash or other property which the Holder would have been entitled to receive pursuant to such Reorganization if such exercise had taken place immediately prior to such Reorganization. In any such case, appropriate adjustment (as determined in good faith by the Board) shall be made in the application of the provisions set forth herein with respect to the rights and interests thereafter of the Holder, to the end that the provisions set forth in this Section 2 (including provisions with respect to changes in and other adjustments of the Purchase Price) shall thereafter be applicable, as nearly as reasonably may be, in relation to any securities, cash or other property thereafter deliverable upon the exercise of this Warrant. (f) Certificate as to Adjustments. Upon the occurrence of each adjustment or readjustment of the Purchase Price pursuant to this Section 2, the Company at its expense shall, as promptly as reasonably practicable but in any event not later than 10 business days thereafter, compute such adjustment or readjustment in accordance with the terms hereof and furnish to the Holder a certificate setting forth such adjustment or readjustment (including the kind and amount of securities, cash or other property for which this Warrant shall be exercisable and the Purchase Price) and the facts upon which such adjustment or readjustment is based. The Company shall, as promptly as reasonably practicable after the written request at any time of the Holder (but in any event not later than 10 business days thereafter), furnish or cause to be furnished to the Holder a certificate setting forth (i) the Purchase Price then in effect and (ii) the number of shares of Common Stock and the amount, if any, of other securities, cash or property which then would be received upon the exercise of this Warrant. -5- (g) No Adjustments in Certain Cases. No adjustment in the number of Warrant Shares purchasable pursuant to this Warrant shall be required unless the adjustment would require an increase or decrease of at least one percent (1.0%) in the number of Warrant Shares then purchasable upon the exercise of this Warrant. Except as provided in this Section 2, no other adjustments in the number, kind or price of shares constituting Warrant Shares shall be made during the term, or upon the exercise, of this Warrant. Further, no adjustments shall be made pursuant to this Section 2 hereof in connection with the grant or exercise of presently authorized or outstanding options to purchase, or the issuance of shares of Common Stock under, the Company's director or employee benefit or option plans. (h) Treasury Stock. For purposes of this Section 2, shares of Common Stock owned or held at any relevant time by, or for the account of, the Company, in its treasury or otherwise, shall not be deemed to be outstanding for purposes of the calculations and adjustments herein described. 3. Fractional Shares. The Company shall not be required upon the exercise of this Warrant to issue any fractional shares, but shall pay in cash to the Holder an amount equal to such fraction multiplied by the Fair Market Value per share of Common Stock, as determined pursuant to subsection 1(b) above. 4. Investment Representations. The initial Holder represents and warrants to the Company as follows: (a) Investment. The Holder is acquiring this Warrant, and (if and when such Holder exercises this Warrant) will acquire the Warrant Shares, for such Holder's own account for investment and not with a view to, or for sale in connection with, any distribution thereof, nor with any present intention of distributing or selling the same; and the Holder has no present or contemplated agreement, undertaking, arrangement, obligation, indebtedness or commitment providing for the disposition thereof. (b) Accredited Investor. The Holder is an "accredited investor" as defined in Rule 501(a) under the Act. (c) Experience. The Holder has made such inquiry concerning the Company and its business and personnel as the Holder has deemed appropriate; and the Holder has sufficient knowledge and experience in finance and business that the Holder is capable of evaluating the risks and merits of an investment in the Company. 5. Transfers, etc. (a) This Warrant and the Warrant Shares shall not be sold or transferred unless either (i) they first shall have been registered under the Act and any applicable state securities laws, or (ii) the Company first shall have been furnished with an opinion of legal counsel, satisfactory to the Company, to the effect that such sale or transfer is exempt from the registration requirements of the Act and any applicable state securities laws. -6- (b) Each certificate representing Warrant Shares shall bear a legend substantially in the following form: "The securities represented by this certificate have not been registered under the Securities Act of 1933, as amended, or any state securities laws, and may not be offered, sold or otherwise transferred, pledged or hypothecated unless and until such securities are registered under such act and applicable state securities laws or an opinion of counsel satisfactory to the Company is obtained to the effect that such registration is not required." The foregoing legend shall be removed from the certificates representing any Warrant Shares, at the request of the holder thereof, at such time as they become eligible for resale pursuant to Rule 144(k) under the Act. (c) The Company will maintain a register containing the name and address of the Holder of this Warrant. The Holder may change the Holder's address as shown on the warrant register by written notice to the Company requesting such change. (d) Subject to the provisions of clauses (a) and (b) of this Section 5, this Warrant and all rights hereunder are transferable, in whole or in part, upon surrender of this Warrant with a properly executed assignment (in the form of Exhibit II hereto) at the principal office of the Company (or, if another office or agency has been designated by the Company for such purpose, then at such other office or agency). Upon the presentation and surrender of such items to the Company, the Company shall execute and deliver to the transferee or transferees of this Warrant a new Warrant or Warrants, in the name of the transferee or transferees named in the assignment, and this Warrant shall at that time be canceled to the extent transferred. 6. No Impairment; Adjustment of Par Value. (a) The Company will not, by amendment of its charter or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the Holder against impairment. (b) Before taking any action that would cause an adjustment reducing the Purchase Price per share below the then par value of the shares of Warrant Shares issuable upon exercise of the Warrant, the Company will take any corporate action that may be necessary in order that the Company may validly and legally issue fully paid and non-assessable shares of such Warrant Shares at such adjusted price. 7. Record Date, etc. In the event: (a) the Company shall take a record of the holders of its Common Stock (or other stock or securities at the time deliverable upon the exercise of this Warrant) for the purpose of entitling or enabling them to receive any dividend or other distribution, or to receive any right to subscribe for or purchase any shares of stock of any class or any other securities, or to receive any other right; or -7- (b) of any capital reorganization of the Company, any reclassification of the Common Stock of the Company, any consolidation or merger of the Company with or into another corporation (other than a consolidation or merger in which the Company is the surviving entity and its Common Stock is not converted into or exchanged for any other securities or property), or any transfer of all or substantially all of the assets of the Company; or (c) of the voluntary or involuntary dissolution, liquidation or winding-up of the Company, then, and in each such case, the Company will send or cause to be sent to the Holder a notice specifying, as the case may be, (i) the record date for such dividend, distribution or right, and the amount and character of such dividend, distribution or right, or (ii) the effective date on which such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or winding-up is to take place, and the time, if any is to be fixed, as of which the holders of record of Common Stock (or such other stock or securities at the time deliverable upon the exercise of this Warrant) shall be entitled to exchange their shares of Common Stock (or such other stock or securities) for securities or other property deliverable upon such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or winding-up. Such notice shall be sent at least 10 days prior to the record date or effective date for the event specified in such notice. 8. Acknowledgment and Reservation of Stock. Commencing the Vesting Date, the Company will at all times reserve and keep available, solely for issuance and delivery upon the exercise of this Warrant, such number of Warrant Shares and other securities, cash and/or property, as from time to time shall be issuable upon the exercise of this Warrant. The Holder expressly agrees and acknowledges that the Company currently does not have for reservation or issuance upon exercise of this Warrant a sufficient number of authorized shares of its Common Stock. 9. Exchange or Replacement of Warrants. (a) Upon the surrender by the Holder, properly endorsed, to the Company at the principal office of the Company, the Company will, subject to the provisions of Section 5 hereof, issue and deliver to or upon the order of the Holder, at the Company's expense, a new Warrant or Warrants of like tenor, in the name of the Holder or as the Holder (upon payment by the Holder of any applicable transfer taxes) may direct, calling in the aggregate on the face or faces thereof for the number of shares of Common Stock (or other securities, cash and/or property) then issuable upon exercise of this Warrant. (b) Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and (in the case of loss, theft or destruction) upon delivery of an indemnity agreement (with surety if reasonably required) in an amount reasonably satisfactory to the Company, or (in the case of mutilation) upon surrender and cancellation of this Warrant, the Company will issue, in lieu thereof, a new Warrant of like tenor. 10. Notices. All notices and other communications from the Company to the Holder in connection herewith shall be mailed by certified or registered mail, postage prepaid, or sent via a reputable nationwide overnight courier service guaranteeing next business day delivery, to the address last furnished to the Company in writing by the Holder. All notices and other communications from the Holder to the Company in connection herewith shall be mailed by certified or registered mail, postage prepaid, or sent via a reputable nationwide overnight courier service guaranteeing next business day delivery, to the Company at its principal office set forth above. If the Company should at any time change the location of its principal office to a place other than as set forth below, it shall give prompt written notice to the Holder and thereafter all references in this Warrant to the location of its principal office at the particular time shall be as so specified in such notice. All such notices and communications shall be deemed delivered (i) three business days after being sent by certified or registered mail, return receipt requested, postage prepaid, or (ii) one business day after being sent via a reputable nationwide overnight courier service guaranteeing next business day delivery. -8- 11. No Rights as Stockholder; No Liability. No provision of this Warrant shall be construed as conferring upon the Holder hereof the right to vote or to consent or to receive dividends or to receive notice as a stockholder in respect of meetings of stockholders for the election of directors of the Company or any other matter whatsoever as a stockholder of the Company. In the absence of affirmative action by the Holder hereof to purchase shares of Common Stock, no provision hereof shall give rise to any liability of such Holder for the purchase price or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company. 12. Payment of Taxes. The Company will pay all documentary stamp taxes, if any, attributable to the initial issuance of this Warrant or the shares of Common Stock comprising the Warrant Shares; provided, however, the Company shall not be required to pay any tax that may be payable in respect of any transfer of this Warrant or Warrant Shares. 13. Amendment or Waiver. Any term of this Warrant may be amended or waived only by an instrument in writing signed by the party against which enforcement of the change or waiver is sought. No waivers of any term, condition or provision of this Warrant, in any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any such term, condition or provision. 14. Section Headings. The section headings in this Warrant are for the convenience of the parties and in no way alter, modify, amend, limit or restrict the contractual obligations of the parties. 15. Severability. If any provision of this Warrant shall be held invalid, illegal or unenforceable, such invalidity, illegality or unenforceability shall not affect any other provision of this Warrant and, to this end, the provisions hereof are severable. 16. Assignment. This warrant shall be binding upon and inure to the benefit of the parties hereto and their respective heirs, personal representatives, successors and permitted assigns. 17. Governing Law. This Warrant will be governed by and construed in accordance with the internal laws of the State of Illinois (without reference to the conflicts of law provisions thereof). -9- 18. Facsimile Signatures. This Warrant may be executed by facsimile signature. EXECUTED as of the Issue Date indicated above. MOLECULAR DIAGNOSTICS, INC. By: -------------------------------------- Title: ----------------------------------- ATTEST: - ----------------------------------- -10- EXHIBIT I PURCHASE FORM To:_________________ Dated:____________ The undersigned, pursuant to the provisions set forth in the attached Warrant (No. ___), hereby elects to purchase (check applicable box): ____ shares of the Common Stock of Molecular Diagnostics, Inc. by such Warrant; or the maximum number of shares of Common Stock covered by such Warrant pursuant to the cashless exercise procedure set forth in subsection 1(b). The undersigned herewith makes payment of the full purchase price for such shares at the price per share provided for in such Warrant. Such payment takes the form of (check applicable box or boxes): $______ in lawful money of the United States; and/or the cancellation of such portion of the attached Warrant as is exercisable for a total of _____ Warrant Shares (using a Fair Market Value of $_____ per share for purposes of this calculation) ; and/or the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 1(b), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 1(b). Signature:__________________________ Address: __________________________ __________________________ -11- EXHIBIT II ASSIGNMENT FORM FOR VALUE RECEIVED, ________________________________________ hereby sells, assigns and transfers all of the rights of the undersigned under the attached Warrant (No. ____) with respect to the number of shares of Common Stock of Molecular Diagnostics, Inc. covered thereby set forth below, unto: Name of Assignee Address No. of Shares Dated:_____________________ Signature:_________________________ Signature Guaranteed: By:_______________________ The signature should be guaranteed by an eligible guarantor institution (banks, stockbrokers, savings and loan associations and credit unions with membership in an approved signature guarantee medallion program) pursuant to Rule 17Ad-15 under the Securities Exchange Act of 1934, as amended. -12- EX-31.1 3 v018881_ex31-1.txt Exhibit 31.1 CERTIFICATION I, Denis M. O'Donnell, M.D., certify that: (1) I have reviewed this quarterly report on Form 10-QSB of Molecular Diagnostics, Inc.; (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; (3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report; (4) The small business issuer's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the small business issuer and have: a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b. evaluated the effectiveness of the small business issuer's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and c. disclosed in this report any change in the small business issuer's internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the small business issuer's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer's internal control over financial reporting; and (5) The small business issuer's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer's auditors and the audit committee of the small business issuer's board of directors (or persons performing the equivalent functions): a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer's ability to record, process, summarize and report financial information; and b. any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer's internal control over financial reporting. /s/ Denis M. O'Donnell, M.D. ------------------------------------- Denis M. O'Donnell, M.D. President and Chief Executive Officer Dated: May 19, 2005 EX-31.2 4 v018881_ex31-2.txt Exhibit 31.2 CERTIFICATION I, Dennis L. Bergquist, certify that: (1) I have reviewed this quarterly report on Form 10-QSB of Molecular Diagnostics, Inc.; (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; (3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report; (4) The small business issuer's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the small business issuer and have: a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b. evaluated the effectiveness of the small business issuer's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and c. disclosed in this report any change in the small business issuer's internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the small business issuer's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer's internal control over financial reporting; and (5) The small business issuer's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer's auditors and the audit committee of the small business issuer's board of directors (or persons performing the equivalent functions): a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer's ability to record, process, summarize and report financial information; and b. any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer's internal control over financial reporting. /s/ Dennis L. Bergquist ------------------------------------- Dennis L. Bergquist Chief Financial Officer Dated: May 19, 2005 EX-32.1 5 v018881_ex32-1.txt Exhibit 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. ss. 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned President and Chief Executive Officer of the Company certifies that, to his knowledge: 1. The Company's Form 10-QSB for the quarter ended March 31, 2005 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. /s/ Denis M. O'Donnell, M.D. ------------------------------------- Denis M. O'Donnell, M.D. President and Chief Executive Officer Dated: May 19, 2005 EX-32.2 6 v018881_ex32-2.txt Exhibit 32.2 CERTIFICATION PURSUANT TO 18 U.S.C. ss. 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned President and Chief Executive Officer of the Company certifies that, to his knowledge: 1. The Company's Form 10-QSB for the quarter ended March 31, 2005 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. /s/ Dennis L. Bergquist ------------------------------------- Dennis L. Bergquist Chief Financial Officer Dated: May 19, 2005 -----END PRIVACY-ENHANCED MESSAGE-----